Pieris Pharmaceuticals, Inc.

Sümbol: PIRS

NASDAQ

11.08

USD

Turuhind täna

-0.5788
P/E suhe
0.0000
PEG suhe
13.70M
MRK Cap
0.00%
DIV tootlus

Pieris Pharmaceuticals, Inc. (PIRS) Finantsaruanded

Q: Mis on Pieris Pharmaceuticals, Inc. (PIRS) koguvara?

Pieris Pharmaceuticals, Inc. (PIRS) koguvara on .

Q: Mis on ettevõtte kasumimarginaal?

Ettevõtte kasumimarginaal on .

Download

Aastane Quarterly

Lineaarne Log

Diagrammil näete Pieris Pharmaceuticals, Inc. (PIRS) vaikimisi numbreid dünaamikates. Companys revenue näitab keskmist 23.101 M, mis on 0.394 % gowth. Kogu perioodi keskmine brutokasum on 13.473 M, mis on 0.403 %. Keskmine brutokasumi suhtarv on 0.751 %. Ettevõtte eelmise aasta tulemuse puhaskasv on -0.215 %, mis on võrdne -13.751 % % keskmiselt kogu ettevõtte ajaloo jooksul.,

Aastane Quarterly

10Y 20Y 30Y 40Y

Bilanss

Sukeldudes Pieris Pharmaceuticals, Inc. fiskaalkäiguteele, täheldame keskmist varade kasvu. See määr on huvitaval kombel , mis kajastab nii ettevõtte kõrg- kui ka madalseisusid. Kui võrrelda kvartalite lõikes, siis kohandub see näitaja 0. Kui vaadata tagasi möödunud aastale, siis on varade kogumuutus -0.595. Käibevara valdkonnas on PIRS aruandlusvaluutas 38.68. Märkimisväärne osa neist varadest, täpsemalt 26.366, hoitakse sularahas ja lühiajalistes investeeringutes. See segment näitab eelmise aasta andmetega võrreldes muutust -0.554%. Ettevõtte pikaajalised investeeringud, kuigi need ei ole tema fookuses, seisavad 0, kui neid on, aruandlusvaluutas. See näitab erinevust 0.000% võrreldes eelmise aruandeperioodiga, mis kajastab ettevõtte strateegilisi muutusi. Ettevõtte võlaprofiil näitab, et ettevõtte pikaajaline koguvõlg on 0 aruandlusvaluutas. See näitaja tähendab, et aastane muutus on -1.000%. Aktsionäride väärtus, mida näitab aktsionäride kogu omakapital, on hinnatud 26.758 aruandlusvaluutas. Selle aspekti aastane muutus on -0.042%. Kui süveneda ettevõtte finantsnäitajatesse, ilmneb täiendavaid üksikasju. Netovõlad on hinnatud 6.039, varude hind on 0 ja firmaväärtus 0, kui see on olemas. Kogu immateriaalne vara, kui see on olemas, hinnatakse 0.

common:word.in-mln USD Growth	TTM	2022	2020	2018	2016	2014
balance-sheet.row.cash-and-short-term-investments	174.43	26.4	59.2	117.8	70.4	104.2	128.1	72.6	29.4	29.3	18.5	3.7
balance-sheet.row.short-term-investments	39.46	9	20.5	0	0	41.9	53.2	34.8	0	0	0	0
balance-sheet.row.net-receivables	11.07	6	5.8	3.3	1.7	6.8	2.7	15.5	0.1	0	0	0.5
balance-sheet.row.inventory	2.1	0	0	0	0	0	0	0	0	0	0	0.1
balance-sheet.row.other-current-assets	37.14	6.3	8.4	6.5	3.6	4.1	4.6	1.6	3.3	2.3	1.3	0.5
balance-sheet.row.total-current-assets	224.75	38.7	73.4	127.6	75.7	115	135.4	89.8	32.7	31.7	19.8	4.8
balance-sheet.row.property-plant-equipment-net	42.47	0	20.7	23	26	22.9	5	4	2.3	2.2	2.1	2.4
balance-sheet.row.goodwill	0	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.intangible-assets	0	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.goodwill-and-intangible-assets	0	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.long-term-investments	0	0	0	0	0	0	0	9.9	0	0	0	0
balance-sheet.row.tax-assets	0	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.other-non-current-assets	0.65	0	1.4	2.9	3.3	3.1	0.9	0.1	0.1	0.1	0	0
balance-sheet.row.total-non-current-assets	43.11	0	22.1	25.9	29.3	26.1	6	14.1	2.4	2.3	2.1	2.5
balance-sheet.row.other-assets	0	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.total-assets	267.86	38.7	95.5	153.6	105	141.1	141.3	103.9	35.1	34	21.9	7.3
balance-sheet.row.account-payables	22.5	3.4	4.2	8.6	3	10.1	3.4	2.5	2.4	1.1	1.3	0.3
balance-sheet.row.short-term-debt	14.09	0	0.9	1	1	0.7	0	4.9	0	0	1.3	0.2
balance-sheet.row.tax-payables	0	0	0	0	0.1	0.5	0.4	0.4	0.5	0.2	0	0
balance-sheet.row.long-term-debt-total	24.12	0	12.2	13.8	15.9	15.5	0	0	0	0	0	4.5
Deferred Revenue Non Current	12.49	0	18.7	38.4	35.9	47.3	53.3	46.5	1.4	0	0	0
balance-sheet.row.deferred-tax-liabilities-non-current	-12.49	-	-	-	-	-	-	-	-	-	-	-
balance-sheet.row.other-current-liab	36.07	8.6	10.7	15.8	5.5	5	9.1	1.3	3.7	1.7	0.2	0.7
balance-sheet.row.total-non-current-liabilities	36.6	0	31	52.2	51.8	62.7	53.3	46.6	1.5	0	0.3	4.9
balance-sheet.row.other-liabilities	0	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.capital-lease-obligations	37.32	0	12.2	13.8	17	16.2	0	0	0	0	0	0
balance-sheet.row.total-liab	154.63	11.9	67.6	102.8	74	89.7	101.4	92.4	9.8	2.8	3.9	6.7
balance-sheet.row.preferred-stock	0	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.common-stock	0.37	0.1	0.1	0.1	0.1	0.1	0.1	0	0	0	0	0
balance-sheet.row.retained-earnings	-1228.58	-315	-290.4	-257.1	-211.4	-174.2	-147.1	-120.3	-102.7	-79.9	-65.8	-56
balance-sheet.row.accumulated-other-comprehensive-income-loss	-0.87	0	-0.3	0.8	-0.3	-2	-3	-4.7	-1.5	-1.3	-0.8	-1
balance-sheet.row.other-total-stockholders-equity	1342.3	341.6	318.5	307	242.7	227.5	189.9	136.5	129.3	112.2	84.6	57.5
balance-sheet.row.total-stockholders-equity	113.22	26.8	27.9	50.8	31	51.4	39.9	11.5	25.2	31.1	18	0.6
balance-sheet.row.total-liabilities-and-stockholders-equity	267.86	38.7	95.5	153.6	105	141.1	141.3	103.9	35.1	34	21.9	7.3
balance-sheet.row.minority-interest	0	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.total-equity	113.22	26.8	27.9	50.8	31	51.4	39.9	-	-	-	-	-
balance-sheet.row.total-liabilities-and-total-equity	267.86	-	-	-	-	-	-	-	-	-	-	-
Total Investments	39.46	9	20.5	0	0	41.9	53.2	44.7	0	0	0	0
balance-sheet.row.total-debt	37.32	0	13.1	13.8	17	16.2	0	0	0	0	1.3	4.8
balance-sheet.row.net-debt	-97.65	-17.4	-25.5	-103.9	-53.5	-46	-74.9	-37.9	-29.4	-29.3	-17.2	1.1

Rahavoogude aruanne

Pieris Pharmaceuticals, Inc. finantsmaastikul on viimase perioodi jooksul toimunud märkimisväärne muutus vabas rahavoos, mis näitab 0.115 nihet. Ettevõte laiendas hiljuti oma aktsiakapitali, emiteerides 19.8, mis tähistab 32.432 erinevust võrreldes eelmise aastaga. Ettevõtte investeerimistegevuse tulemusel kasutas ettevõte netosularaha, mis aruandlusvaluutas oli 12002000.000. See on -1.565 nihkumine võrreldes eelmise aastaga. Samal perioodil registreeris ettevõte 1.78, 0, 0, mis on olulised ettevõtte investeerimis-ja tagasimaksestrateegiate mõistmiseks. Ettevõtte finantseerimistegevuse tulemusel kasutas ettevõte netorahavahendeid 0.000, kusjuures erinevus võrreldes eelmise aastaga oli 0.000. Lisaks eraldas ettevõte 0 aktsionäridele dividendide maksmiseks. Samal ajal tegi ta muid finantsmanöövreid, millele viidatakse kui 0.07, mis samuti mõjutasid oluliselt tema rahavooge sel perioodil. Need komponendid koos annavad tervikliku pildi ettevõtte finantsseisundist ja strateegilisest lähenemisest rahavoogude juhtimisele.

common:word.in-mln USD Growth	TTM	2022	2020	2018	2016	2014
cash-flows.row.net-income	-24.54	-24.5	-33.3	-45.7	-37.2	-25.5	-26.8	-17.6	-22.8	-14.1	-9.8	0.1
cash-flows.row.depreciation-and-amortization	1.81	1.8	2.8	2.4	2.1	1	0.6	0.4	0.4	0.3	0.4	0.4
cash-flows.row.deferred-income-tax	14.53	-4.5	0	0	0.2	-1.2	-0.2	0.2	-1.9	0	0.7	0
cash-flows.row.stock-based-compensation	3.35	3.3	4.4	5.2	5.1	5.4	4.9	3	1.9	1.2	0.6	0
cash-flows.row.change-in-working-capital	-48.14	-48.1	-33.4	30.5	-16.4	-32.1	21.9	63.5	6.1	-0.8	0.6	-3.9
cash-flows.row.account-receivables	5.31	5.3	-2.6	-1.8	5.3	-4.1	12.5	-14.5	-0.1	0	0.5	-0.3
cash-flows.row.inventory	0	0	0	5.7	-2.9	-0.8	0	4	1	0	-1.1	-3.2
cash-flows.row.account-payables	-0.79	-0.8	-4.2	7	-4.4	1.3	0.8	-0.3	1.4	-0.1	1.1	-0.5
cash-flows.row.other-working-capital	-12.71	-52.7	-26.5	19.6	-14.5	-28.5	8.6	74.4	3.8	-0.7	0.1	0.1
cash-flows.row.other-non-cash-items	-0.82	18.3	-0.5	0	0.3	-0.1	-1.6	0.3	1.9	0.7	2.6	0.4
cash-flows.row.net-cash-provided-by-operating-activities	-53.82	0	0	0	0	0	0	0	0	0	0	0
cash-flows.row.investments-in-property-plant-an-equipment	-0.17	-0.2	-1	-0.9	-2.7	-2.5	-1.7	-1.9	-0.6	-0.6	-0.3	0
cash-flows.row.acquisitions-net	-12.17	0	20.2	0	-41.9	-12.3	0	0	0	0	0	0
cash-flows.row.purchases-of-investments	-22.84	-22.8	-48.4	0	-41.5	-59.3	-117.6	-43.9	0	0	0	0
cash-flows.row.sales-maturities-of-investments	35.01	35	28.2	0	83.4	71.6	110.4	0	0	0	0	0
cash-flows.row.other-investing-activites	12.17	0	-20.2	0	41.9	12.3	0	0	0	0	0	0
cash-flows.row.net-cash-used-for-investing-activites	12	12	-21.2	-0.9	39.2	9.8	-8.9	-45.9	-0.6	-0.6	-0.3	0
cash-flows.row.debt-repayment	0	0	-1	0	0	0	0	0	0	-1.2	-0.2	0
cash-flows.row.common-stock-issued	19.74	19.8	6.9	57.1	9.6	31	47.2	0	15.2	25.8	12	0
cash-flows.row.common-stock-repurchased	0	0	0	0	0	0	0	0	0	0	0	0
cash-flows.row.dividends-paid	0	0	0	0	0	0	0	0	0	0	0	0
cash-flows.row.other-financing-activites	0.07	0.1	1.3	2	0.5	1.2	1.3	4.1	0	0	8.6	0.3
cash-flows.row.net-cash-used-provided-by-financing-activities	19.8	19.8	7.2	59.1	10.1	32.2	48.5	4.1	15.2	24.6	20.3	0.3
cash-flows.row.effect-of-forex-changes-on-cash	0.78	0.8	-5.2	-3.2	4.7	-2.1	-1.6	0.6	-0.3	-0.4	-0.2	0.2
cash-flows.row.net-change-in-cash	-21.24	-21.2	-79.1	47.3	8.2	-12.6	37	8.5	0	10.9	14.8	-2.6
cash-flows.row.cash-at-end-of-period	134.97	17.4	38.6	117.8	70.4	62.3	74.9	37.9	29.4	29.3	18.5	3.7
cash-flows.row.cash-at-beginning-of-period	156.21	38.6	117.8	70.4	62.3	74.9	37.9	29.4	29.3	18.5	3.7	6.3
cash-flows.row.operating-cash-flow	-53.82	-53.8	-59.9	-7.7	-45.9	-52.5	-1.1	49.8	-14.4	-12.7	-5.1	-3.1
cash-flows.row.capital-expenditure	-0.17	-0.2	-1	-0.9	-2.7	-2.5	-1.7	-1.9	-0.6	-0.6	-0.3	0
cash-flows.row.free-cash-flow	-53.99	-54	-61	-8.6	-48.6	-54.9	-2.8	47.8	-15	-13.3	-5.3	-3.1

Kasumiaruande rida

Pieris Pharmaceuticals, Inc. tulud muutusid võrreldes eelmise perioodiga 0.653%. PIRS brutokasum on teatatud 41.03. Ettevõtte tegevuskulud on 56.87, mille muutus võrreldes eelmise aastaga on -7.075%. Kulud amortisatsioonikulud on 1.78, mis on -0.782% muutus võrreldes eelmise aruandeperioodiga. Tegevuskulud on teatatud 56.87, mis näitab -7.075% muutust võrreldes eelmise aastaga. Müügi- ja turunduskulud on 0, mis on 0.000% muutus võrreldes eelmise aastaga. Hiljutistel numbritel põhinev EBITDA on 0, mis tähendab 0.636% kasvu võrreldes eelmise aastaga. Tegevustulu on -15.84, mis näitab -0.636% muutust võrreldes eelmise aastaga. Puhaskasumi muutus on -0.215%. Eelmise aasta puhaskasum oli -24.54.

common:word.in-mln USD Growth	TTM	2022	2020	2018	2016	2014
income-statement-row.row.total-revenue	42.81	42.8	25.9	31.4	29.3	46.3	29.1	25.3	5.8	2.9	5.4	9.9
income-statement-row.row.cost-of-revenue	6.49	1.8	2.8	2.4	46.5	55	0	0	0	0	0	0
income-statement-row.row.gross-profit	36.32	41	23.1	29.1	-17.2	-8.7	29.1	25.3	5.8	2.9	5.4	12.4
income-statement-row.row.gross-profit-ratio	0	0	0	0	0	0	0	0	0	0	0	0
income-statement-row.row.research-development	41.8	-	-	-	-	-	-	-	-	-	-	-
income-statement-row.row.selling-general-administrative	16.85	-	-	-	-	-	-	-	-	-	-	-
income-statement-row.row.selling-and-marketing-expenses	0	-	-	-	-	-	-	-	-	-	-	-
income-statement-row.row.other-expenses	13.91	13.9	-8.2	-3.7	-3.7	0	1.8	-2.1	0.1	0	0	0
income-statement-row.row.operating-expenses	55.04	56.9	61.2	79.6	63.2	73.4	59.9	39.9	28.6	16.6	12.6	9.3
income-statement-row.row.cost-and-expenses	55.04	58.7	61.2	79.6	63.2	73.4	59.9	39.9	28.6	16.6	12.6	9.3
income-statement-row.row.interest-income	1.85	1.9	0.7	0	0.5	1.7	2	0.2	0	0	0	0
income-statement-row.row.interest-expense	0	0	-10.2	0	0	0	-3.8	1.9	0	0.2	2.7	0.5
income-statement-row.row.selling-and-marketing-expenses	0	-	-	-	-	-	-	-	-	-	-	-
income-statement-row.row.total-other-income-expensenet	-11.32	-8.7	10.2	6.1	-3.1	1.7	3.8	-2.1	0.1	0	0	0
income-statement-row.row.ebitda-ratio-caps	0	-	-	-	-	-	-	-	-	-	-	-
income-statement-row.row.other-operating-expenses	13.91	13.9	-8.2	-3.7	-3.7	0	1.8	-2.1	0.1	0	0	0
income-statement-row.row.total-operating-expenses	-11.32	-8.7	10.2	6.1	-3.1	1.7	3.8	-2.1	0.1	0	0	0
income-statement-row.row.interest-expense	0	0	-10.2	0	0	0	-3.8	1.9	0	0.2	2.7	0.5
income-statement-row.row.depreciation-and-amortization	3.94	1.8	8.2	3.7	2.1	1	0.6	0.4	0.4	0.3	0.4	0.4
income-statement-row.row.ebitda-caps	3.87	-	-	-	-	-	-	-	-	-	-	-
income-statement-row.row.operating-income	-30.74	-15.8	-43.5	-51.8	-33.9	-27.2	-30.8	-14.6	-22.8	-13.7	-7.2	0.6
income-statement-row.row.income-before-tax	-24.54	-24.5	-33.3	-45.7	-37.1	-25.5	-27.1	-16.5	-22.6	-13.9	-9.8	0.1
income-statement-row.row.income-tax-expense	12.28	0	-2	-2.4	0.2	-1.7	-0.3	1.1	0.2	0.2	0	0.5
income-statement-row.row.net-income	-23.67	-24.5	-31.3	-43.4	-37.2	-23.8	-26.8	-17.6	-22.8	-14.1	-9.8	0.1